Are you or your loved ones suffering from recurrent neuroendocrine tumor?

You may be eligible to participate in a recurrent neuroendocrine tumor clinical trial.

Are you or your loved ones suffering from recurrent neuroendocrine tumor? You may be eligible to participate in a recurrent neuroendocrine tumor clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Neuroendocrine Tumors
NCT03034200 | Phase 2 | Interventional
What you may receive

Study related treatment at no cost

Peter Anderson
Sponsored by
Peter Anderson

Are you or your loved ones suffering from recurrent neuroendocrine tumor?

You may be eligible to participate in a recurrent neuroendocrine tumor clinical trial.

Are you or your loved ones suffering from recurrent neuroendocrine tumor? You may be eligible to participate in a recurrent neuroendocrine tumor clinical trial.

Recruiting

Male & Female

18 +

years old

The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in participants (metastases). A phase 2 study of ONC201 in PC-PG (pheochromocytoma-paraganglioma) and other neuroendocrine tumors will determine whether inhibition of DRD2 (a member of the dopamine receptor family) is safe in neuroendocrine cancers including PC-PG. ONC201 is an investigational (experimental) agent and has a favorable safety profile in phase 1 and early phase 2 clinical trials in advanced cancers. This study design has been chosen to see whether ONC201 is associated with reduction of anti-hypertension medications, safety and significant efficacy against neuroendocrine tumors, especially PC-PG.

Where you'll go

Selected location

Interested in participating?

Selected location

Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center

Cleveland, OH, USA 44195

Peter M Anderson, MD, PhD 216-445-4007


By clicking the button, you agree to the Terms and Privacy Policy.

Sign up now